Fabrication of Electroluminesecent Thin Films Doped with Rare-Earth Ions by Evaporation Method

The fabrication conditions of the electroluminescent ZnS:TbF₃, ZnS:ErF₃, and ZnS;NdF₃ thin films have been investigated. The effects of pre-heating upon the electroluminescent properties, and the relationship between crucible temperature and deposition rate, have been studied. The optimum fabrication conditions of the strong electroluminescent films have been found to be as fol1ows; crucible temperature for ZnS of 760～780℃, crucible temperature for rare-earth fluorides of 780～820℃, and the deposition rate of 300Å/min. These conditions were independent of the rare-earth ions doped. The EL emission spectra of the films have been related to known energy level schemes of doped rare-earth ions. The external power efficiency of 5×10⁶ have been obtained

The Electrical Characteristics of Anodic Oxidized Ta₂O₅ Films

The dielectric constant, the dielectric　loss, the breakdown voltage and the current at high electric fields of Ta₂O₅ 1ayers have been measured using Ta-Ta₂O₅-Au devices with various thicknesses. The Ta₂O₅ layer is prepared by anodizing sputtered Ta films. The rate of anodic oxidation is about 16-18Å/V. The Ta-Ta₂O₅-Au devices with the Ta₂O₅ layers more than 1500Å thick are electrically stable and show the dielectric constants of 20-25, which are slightly smaIIer than those of bulk (25-27). The current at high electric fields depends strongly upon temperature and therefore is considered to be the Schottky current. The breakdown electric field is about 5x10⁶V/cm. A few of the Ta-Ta₂O₅-Au devices studied show the remarkable rectifying characteristics, which may be due to the n― i―p junction of the Ta₂O₅ 1ayer

Crystal Growth of Rare‐Earth Pentaphosphates

The crystal growth conditions and some opticaI properties for neodymium pentaPhosphate crystals (NdP₅O₁₄) have been studied. The size, shape and quality of crystals are much affected by crystal growth conditions. The optically high quality crystals are obtained from phosphoric acid solution of the weight concentration ratio of 40 : 1 of H₃PO₄ and Nd₂O₃ at the temperature of about 500℃ in saturated water-vapour pressure. The crystals obtained are 2～4 mm in size, and 0.4～l mm in thikness, and their shapes are hexagonal plates. The absorption coefficient is intensitive to crystal growth cnditions, being nearly 13.l cm⁻¹ at 514.5 nm　excitation of Ar laser. The emission peaks are 0.89 μm and l.05 μm with linewidth of adout 10 nm. The lifetime is slightly affected by crystal growth temperature. The lifetime measured are 120 μs and 100 μs respectively, for growth temperature of 550℃ and 500℃

Design of Picosecond Modelocked Nd : YAG Laser

Infrared picosecond puIse trains(～7 ns pulse separation) have been obtained from a passive modelocked Nd : YAG laser, Modelocking is achieved by a saturable absorber dye(NDL l12)in 1,2-dichloroethane. The pulse duration is measured by TPF technique to be～30 ps. The efficiency with which energy is transfered from a lamp to the Nd : YAG rod is determined by the delay time of emission from a krypton flashlamp. By varying the impedance characteristics of the krypton flashlamp, the optimum delay time (～105 μs) is obtained. In order to generate the stable picosecond pulse ( ～3 percent fluctuation), the output voltage fluctuation of Power supply must be held within ～2 percent. The SHG (532 nm) and the THG (355 nm) of picosecond pulses from the Nd : YAG laser were also obtained by using KDP(KH₂ P0₄)crystals of Type I and Type II Phase-matching, respectively

ディジタル ライブラリ ニオケル リレキ コジン ジョウホウ ノ ホゴ オヨビ リヨウ

電子図書館サービスの多くは、従来からある図書館サービスを電子的に行うことにより、図書館員が行う作業の効率化や資料への効率的なアクセスを実現するものであり、新たなサービスを提供するものは少ない。筆者らの研究グループは新たな電子図書館サービス構築を目指し研究を進めており、その過程で個人情報を含んだ貸出履歴をサービスに使うことの是非が大きな問題点として浮上した。本稿では、図書館の役割や利用者の個人情報について考察し、新たな電子図書館のサービスによる利便性向上と個人情報保護を両立するモデルを提案する

Monocyte or white blood cell counts and β₂ microglobulin predict the durable efficacy of daratumumab with lenalidomide

BACKGROUND: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. OBJECTIVES: We hypothesized that a durable response to daratumumab could be predicted by the balance between the MM tumor burden and host immune status. DESIGN: We conducted a retrospective study using the real-world data in the Kansai Myeloma Forum (KMF) database. METHODS: We retrospectively analyzed 324 relapsed/refractory MM patients who were treated with daratumumab in the KMF database. RESULTS: In this study, 196 patients were treated with daratumumab, lenalidomide, and dexamethasone (DLd) regimen and 128 patients were treated with daratumumab, bortezomib, and dexamethasone (DBd) regimen. The median age at treatment, number of prior treatment regimens and time-to-next-treatment (TTNT) were 68, 4 and 8.02 months, respectively. A multivariate analysis showed that the TTNT under the DLd regimen was longer with either higher monocyte counts (analysis 1), higher white blood cell (WBC) counts (analysis 2), lower β2 microglobulin (B2MG < 5.5 mg/L) or fewer prior regimens (<4). No parameters were correlated with TTNT under the DBd regimen. CONCLUSION: We propose a simple scoring model to predict a durable effect of the DLd regimen by classifying patients into three categories based on either monocyte counts (0 points for ⩾200/μl; 1 point for <200/μl) or WBC counts (0 points for ⩾3500/μl; 1 point for <3500/μl) plus B2MG (0 points for <5.5 mg/L; 1 point for ⩾5.5 mg/L). Patients with a score of 0 showed significantly longer TTNT and significantly better survival compared to those with a score of 1 or 2 (both p < 0.001). To confirm this concept, our results will need to be validated in other cohorts

Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy and safety in 157 patients registered in the Kansai Myeloma Forum database. Results: A total of 107 patients received KRd. Before KRd, 99% of patients had received bortezomib (54% were refractory disease), and 82% had received lenalidomide (57% were refractory disease). The overall response rate (ORR) was 68.2%. The median progression-free survival (PFS) and overall survival (OS) were 8.8 and 29.3 months, respectively. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein were significantly associated with lower PFS and reduction of the carfilzomib dose and refractoriness to prior bortezomib-based regimens were significantly associated with lower OS. A total of 50 patients received Kd. Before Kd, 96% of patients had received bortezomib (54% were refractory disease). The ORR was 62.0%. The median PFS and OS were 7.1 and 20.9 months, respectively. Based on the multivariate analysis, reduction of the carfilzomib dose and International Staging System Stage III (ISS III) were significantly associated with lower PFS. Grade III or higher adverse events were observed in 48% of KRd cases and 54% of Kd cases. Cardiovascular events, cytopenia, and infections were frequent, and 4 KRd patients died due to heart failure, arrhythmia, cerebral hemorrhage, and pneumonia. Conclusion: Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered